MedPath

ADHD and EEG-Neurofeedback. A randomised placebo-controlled treatment study

Phase 3
Completed
Conditions
Attention-deficit / Hyperactivity Disorder (ADHD)
10034726
Registration Number
NL-OMON32034
Lead Sponsor
niversitair Medisch Centrum Sint Radboud
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
41
Inclusion Criteria

Diagnosis ADHD (classified by the DSM-IV TR)
Age between 8 and 15
A full scale IQ ³ 80
Medication- naïve, or using psychostimulants/atomoxetine but still with room for improvement

Exclusion Criteria

Currently intensive (i.e. weekly) individual or group psychotherapy.
Use of medication other than psychopharmaca
Diagnosis of one or more of the following comorbid psychiatric disorders:
Major depression or dysthymie
Anxiety disorder
Bipolar disorder
Psychotic disorder
Chronical motor tic disorder or Gilles de la Tourette
Conduct disorder
Autism spectrum disorders
Eating disorders
Cardiovascular disease currently/in the past
Neurological disorders (e.g. epilepsy) currently or in the past
Participation in another clinical trial simultaneously
Neurofeedback training in the past
Metal parts in body

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>ADHD-DSM-IV rating scale, rated by the investigator</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>scores on all neuropsychological tasks<br /><br>absolute en relative power of 4 frequenties EEG bands<br /><br>fluctuations in de BOLD signals on fMRI<br /><br>measures on the diffusion Tensor Imaging (DTI)</p><br>
© Copyright 2025. All Rights Reserved by MedPath